Compare D Wave Quantum Inc (QBTS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Recursion Pharmaceuticals Inc — how do they compare? D Wave Quantum Inc trades at $17.36 (market cap $6.59B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: D Wave Quantum Inc is far larger — about 4× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| QBTS | RXRX | |
|---|---|---|
Market Cap | $6.59B | $1.63B |
Sector | Technology | Health |
52-Week High | $44.78 | $6.79 |
52-Week Low | $12.98 | $2.84 |
Enterprise Value | $6.05B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QBTS trades at $16.73, showing no change in the last 24 hours. The stock is technically bearish with key support at $16 and resistance at $17. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million revenue in 2025, with a negative net income margin of -2,957.23%. Recent news highlights D-Wave's dual-platform quantum computing approach and a recent transfer of its stock listing to Nasdaq (Business Wire, July 14, 2026).
Despite unanimous analyst buy ratings and a $39.86 consensus price target implying significant upside, QBTS faces substantial execution risks. High cash burn, negative profitability, and intense competition in the emerging quantum computing sector present challenges. The stock's appeal hinges on future revenue growth materializing from current commercial partnerships and technological advancements.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
